Increased Response to Ketamine Following Treatment at Long Intervals: Implications for Intermittent Use

Biological Psychiatry

Volumn 63, Issue 2, 2008, Pages 178-183

  Trujillo, Keith A ^a   Zamora, Juan J ^a   Warmoth, Kathleen P ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Environment; ketamine; locomotor behavior; neuroadaptation; rave; sensitization

Indexed keywords

KETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG SENSITIZATION; ENVIRONMENTAL EXPOSURE; LOCOMOTION; MALE; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; STIMULATION;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; KETAMINE; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 37349075426     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.02.014     Document Type: Article

References (50)

1. Domino E.F. Status of Ketamine in Anesthesiology (1990), NPP Books, Ann Arbor, MI
2. Kennedy S.K., and Longnecker D.E. General anesthetics. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. (1996), McGraw-Hill, New York 307-330
3. Bell R.F., Dahl J.B., Moore R.A., and Kalso E. Peri-operative ketamine for acute post-operative pain: A quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand 49 (2005) 1405-1428
4. Bell R.F., and Kalso E. Is intranasal ketamine an appropriate treatment for chronic non-cancer breakthrough pain?. Pain 108 1-2 (2004) 1-2
5. Carr D.B., Goudas L.C., Denman W.T., et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: A randomized, double-blind, placebo-controlled, crossover study. Pain 108 1-2 (2004) 17-27
6. Subramaniam K., Subramaniam B., and Steinbrook R.A. Ketamine as adjuvant analgesic to opioids: A quantitative and qualitative systematic review. Anesth Analg 99 (2004) 482-495 table of contents
7. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000) 351-354
8. Zarate Jr. C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006) 856-864
9. Becker A., Peters B., Schroeder H., Mann T., Huether G., and Grecksch G. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 687-700
10. Lahti A.C., Koffel B., LaPorte D., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 (1995) 9-19
11. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., and Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology 169 (2003) 215-233 (Berl)
12. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
13. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., et al. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996) 301-307
14. Dillon P., Copeland J., and Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 69 (2003) 23-28
15. Jansen K.L. A review of the nonmedical use of ketamine: Use, users and consequences. J Psychoactive Drugs 32 (2000) 419-433
16. Jansen K.L., and Darracot-Cankovic R. The nonmedical use of ketamine, part two: A review of problem use and dependence. J Psychoactive Drugs 33 (2001) 151-158
17. Copeland J., and Dillon P. The health and psycho-social consequences of ketamine use. Int J Drug Policy 16 (2005) 122-131
18. Freese T.E., Miotto K., and Reback C.J. The effects and consequences of selected club drugs. J Subst Abuse Treat 23 (2002) 151-156
19. Hansen G., Jensen S.B., Chandresh L., and Hilden T. The psychotropic effect of ketamine. J Psychoactive Drugs 20 (1988) 419-425
20. Substance Abuse and Mental Health Services Administration. Trends in Drug-Related Emergency Department Visits, 1994-2001 at a Glance, The DAWN Report (2003), Substance Abuse and Mental Health Services Administration, Rockville, MD
21. Drug Enforcement Administration. News Release: DEA to Control "Special K" for the First Time (1999). http://www.usdoj.gov:80/dea/pubs/pressrel/pr071399.htm Available at: http://www.usdoj.gov:80/dea/pubs/pressrel/pr071399.htm. Accessed January 9, 2007.
22. Robinson T.E., and Berridge K.C. Addiction. Annu Rev Psychol 54 (2003) 25-53
23. Wolf M.E. NMDA receptors and behavioral sensitization: Beyond dizocilpine. Trends Pharmacol Sci 20 (1999) 188-189
24. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res Brain Res Rev 31 (2000) 371-384
25. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animals models of amphetamine psychosis. Brain Res Rev 11 (1986) 157-198
26. Hance A.J., Winters W.D., Quam D.D., Benthuysen J.L., and Cadd G.G. Catalepsy induced by combinations of ketamine and morphine: Potentiation, antagonism, tolerance and cross-tolerance in the rat. Neuropharmacology 28 (1989) 109-116
27. Winters W.D., Hance A.J., Cadd G.G., Quam D.D., and Benthuysen J.L. Ketamine- and morphine-induced analgesia and catalepsy. I. Tolerance, cross-tolerance, potentiation, residual morphine levels and naloxone action in the rat. J Pharmacol Exp Ther 244 (1988) 51-57
28. Livingston A., and Waterman A.E. The development of tolerance to ketamine in rats and the significance of hepatic metabolism. Br J Pharmacol 64 (1978) 63-69
29. Byer D.E., and Gould Jr. A.B. Development of tolerance to ketamine in an infant undergoing repeated anesthesia. Anesthesiology 54 (1981) 255-256
30. Cumming J.F. The development of an acute tolerance to ketamine. Anesth Analg 55 (1976) 788-791
31. MacLennan F.M. Ketamine tolerance and hallucinations in children. Anaesthesia 37 (1982) 1214-1215
32. Cho H.S., D'Souza D.C., Gueorguieva R., Perry E.B., Madonick S., Karper L.P., et al. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology 179 (2005) 136-143 (Berl)
33. Leccese A.P., Marquis K.L., Mattia A., and Moreton J.E. The anticonvulsant and behavioral effects of phencyclidine and ketamine following chronic treatment in rats. Behav Brain Res 22 (1986) 257-264
34. Lannes B., Micheletti G., Warter J.M., Kempf E., and Di Scala G. Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci Lett 128 (1991) 177-181
35. Nelson C.L., Burk J.A., Bruno J.P., and Sarter M. Effects of acute and repeated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats. Psychopharmacology 161 (2002) 168-179 (Berl)
36. Uchihashi Y., Kuribara H., Morita T., and Fujita T. The repeated administration of ketamine induces an enhancement of its stimulant action in mice. Jpn J Pharmacol 61 (1993) 149-151
37. Edwards S.R., Minto C.F., and Mather L.E. Concurrent ketamine and alfentanil administration: Pharmacokinetic considerations. Br J Anaesth 88 (2002) 94-100
38. Hanania T., Hillman G.R., and Johnson K.M. Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit. Synapse 31 (1999) 229-239
39. Melnick S.M., Rodriguez J.S., Bernardi R.E., and Ettenberg A. A simple procedure for assessing ataxia in rats: Effects of phencyclidine. Pharmacol Biochem Behav 72 (2002) 125-130
40. Sturgeon R.D., Fessler R.G., London S.F., and Meltzer H.Y. Behavioral effects of chronic phencyclidine administration in rats. Psychopharmacology 76 (1982) 52-56 (Berl)
41. Anis N.A., Berry S.C., Burton N.R., and Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79 (1983) 565-575
42. Johnson K.M., Phillips M., Wang C., and Kevetter G.A. Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res 52 (1998) 709-722
43. Phillips M., Wang C., and Johnson K.M. Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther 296 (2001) 905-913
44. Xu X., and Domino E.F. Phencyclidine-induced behavioral sensitization. Pharmacol Biochem Behav 47 (1994) 603-608
45. Xu X., and Domino E.F. A further study on asymmetric cross-sensitization between MK-801 and phencyclidine-induced ambulatory activity. Pharmacol Biochem Behav 63 (1999) 413-416
46. Wang C., Showalter V.M., Hillman G.R., and Johnson K.M. Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain. J Neurosci Res 55 (1999) 762-769
47. Badiani A., and Robinson T.E. Drug-induced neurobehavioral plasticity: The role of environmental context. Behav Pharmacol 15 (2004) 327-339
48. Pert A., Post R., and Weiss S.R.B. Conditioning as a critical determinant of sensitization induced by psychomotor stimulants. NIDA Res Monogr 97 (1990) 208-240
49. Robinson T.E., Browman K.E., Crombag H.S., and Badiani A. Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 22 (1998) 347-354
50. Stewart J., and Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 4 (1993) 289-312